MedTrace Logo

Role of Simvastatin in Relapsing-Remitting Multiple Sclerosis

NCT04178980 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-11-29

No results posted yet for this study

Summary

The purpose of the clinical trial is to test how Simvastatin (80mg/day) may decrease attacks and progression of disease in patients with multiple sclerosis under disease modifying therapy (DMTs)

Conditions

  • Simvastatin Multiple Sclerosis

Interventions

DRUG

Simvastatin in relapsing remitting multiple sclerosis

Simvastatin use as adjuvant thearapy in relapsing remitting multiple sclerosis

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-01-01
Completion
2022-03-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04178980 on ClinicalTrials.gov